GlassScriptPhysician profile
Jessaca Higginbotham
NPI 1285136507
$5,586.06
in general payments reported to CMS, 2019-2025
21 companies · $877 in 2025
The $877 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,197 · 2023: $2,067 · 2024: $1,445 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.71 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.49 | 2022-2025 | |
| Incyte Corporation | $615.73 | 2022-2025 | Opzelura, Iclusig |
| Novartis Pharmaceuticals Corporation | $549.74 | 2022-2025 | |
| Leo Pharma INC. | $498.66 | 2022-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $497.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $460.66 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $310.82 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $254.60 | 2022-2025 | Winlevi, Blu-U |
| Dermavant Sciences, INC. | $223.64 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $199.89 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $175.44 | 2023-2024 | Epsolay, Aklief |
| Ucb, INC. | $124.99 | 2024 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $124.25 | 2022-2024 | Dupixent |
| Mylan Specialty L.P. | $118.27 | 2022 | |
| Arcutis Biotherapeutics, INC. | $108.33 | 2023-2024 | Zoryve |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $85.44 | 2023-2024 | |
| Amgen INC. | $60.82 | 2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.91 | 2023-2024 | Jublia, Arazlo, Duobrii |
| Helsinn Therapeutics (U.S.), INC. | $43.09 | 2022-2023 | Valchlor |
| Organon LLC | $29.55 | 2025 | Nexplanon, Vtama |
| Biofrontera INC. | $6.05 | 2024 | Ameluz, Rhodoled Xl, Xepi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessaca Higginbotham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.